60% of IV Fluid Production Disrupted! The U.S. Healthcare System Faces a Severe Shortage Crisis, FDA Urgently Imports Foreign Drugs

Recently, the U.S. Food and Drug Administration (FDA) revealed that Hurricane Helen caused significant damage to an important manufacturing facility in North Carolina, further exacerbating an IV infusion shortage that has been ongoing for some time. The plant is responsible for producing about 60 percent of the intravenous fluids used in U.S. hospitals, so its shutdown has had a major impact on the health care system. To alleviate this shortage, the FDA has begun importing products from overseas to ensure that patients receive the treatment they need in a timely manner.

At the same time, the European Medicines Agency (EMA) also reported a worrying trend: growing shortages of essential medicines, including antibiotics and cancer treatments, due to production disruptions and regulatory challenges. In response to this crisis, the European Union launched a coalition aimed at strengthening cooperation among its 23 member states to ensure the stability and reliability of the drug supply chain.

These seemingly unrelated and geographically dispersed examples actually highlight the pharmaceutical industry's dependence on fragile supply chains, which further underscores the urgent need to reevaluate and restructure supply chains. According to a KPMG report, the US leads the generic market with a prescribing rate of around 90 per cent, while prescribing practices across Europe show a similar trend.

"Global demand for generics continues to grow as payers and consumers look for ways to cut healthcare costs," KPMG noted. However, despite the rise in demand, buyers in the market are also consolidating, creating more leverage in pricing. That means increased profit pressure on suppliers and the increasing likelihood that manufacturers will exit unprofitable products.

As a result, some companies are under intense pressure to ramp up production to meet soaring demand while maintaining drug efficacy and safety standards. This double pressure makes quality problems one of the main reasons for drug shortages. In addition, many drug manufacturers lack real-time inventory data, which hampers their ability to effectively manage supply. Inadequate communication among manufacturers, pharmacies and hospitals further complicates efforts to anticipate and address shortages.

Visibility and collaboration are key to addressing these inefficiencies and thus achieving supply chain resilience. From raw materials to finished products, real-time inventory tracking enables pharmaceutical companies to significantly improve visibility and facilitate agile decision making. Suppose manufacturers predict potential shortages by analyzing current inventory levels of active ingredients; This enables them to proactively adjust production schedules.

It also enables healthcare providers to effectively manage inventory levels and prevent overstocking or out of stock of critical drugs. This allows the industry to detect disruptions early, such as delays in procurement or materials, and take proactive action before these problems turn into serious shortages. In addition, leveraging predictive analytics enables companies to simulate various scenarios and develop contingency plans, ensuring they are prepared for potential disruptions. By analyzing historical data, market trends, production capacity, regulatory changes, and previous shortage events, the pharmaceutical chain can provide accurate forecasts.

This proactive approach allows healthcare systems to adjust inventory levels in advance or secure alternative suppliers. If one facility is affected by a natural disaster, others can continue to operate, ensuring the supply of essential medicines. However, visibility alone will not unlock the full potential of the supply chain. Communication must be enhanced as medicines move from manufacturer to distributor to hospital.

A whole cycle of communication needs to be established between various stakeholders, including suppliers, healthcare providers, and regulators, so that manufacturers can match their production rates to actual usage. This smooth flow of data allows organizations to better coordinate responses during shortages. Only 14 percent of drugs in clinical trials are approved by the FDA, resulting in an average development cost of $1 billion per approved drug. This financial burden underscores the need for more efficient processes, and commercial AI has the potential to be the missing ingredient.

Gilead Sciences, Inc., a biopharmaceutical company, is co-innovating with SAP to develop the SAP Life Sciences Batch Release Center. The tool performs control checks on manufactured drug batches to help organizations maintain compliance with regulatory standards across regions. The rise of generative AI has allowed researchers to explore a wider range of potential compounds than traditional methods. It can be used to detect disease patterns across a wide range of data sets, helping to determine the best drug compositions for a variety of conditions.

By leveraging AI, the pharmaceutical industry can reduce research and development costs, minimize human error, shorten research times, and make essential medicines more accessible, affordable, and profitable. While the global drug shortage is a complex challenge that will not be solved quickly, prioritizing cooperation, transparency, and proactive strategies can help build a more resilient drug supply chain.